Nipocalimab for Generalised Myasthenia Gravis

Nipocalimab is currently in clinical development for the treatment of adults with generalised myasthenia gravis (gMG). gMG is a rare, long-term autoimmune disorder that leads to muscle weakness and tiredness, which can be seriously debilitating and life-threatening, affecting eye alignment, swallowing, speech, mobility and respiratory function. These symptoms can significantly impair independence and quality of life. gMG is caused by the body’s immune system wrongly launching an attack against the neuromuscular junction — the place where nerve cells communicate with muscle cells. This attack is largely driven by self-reactive antibodies, also known as autoantibodies, and more specifically, by immunoglobulin G (IgG) autoantibodies. Current treatments have long-term side effects, which can be intolerable for patients, and can take several months to become effective.